18 The tool contains seven domains, which are random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, ...

When we think of the symptoms of major depressive disorder (MDD) we typically think of persistent feelings of sadness, lack ...

New research published in Annals of Family Medicine identifies five clinically relevant prescribing cascades in a national sample of more than half a million older adults in Ireland. The findings show ...

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI), TAAR1 agonist, and 5-HT 1A agonist being developed ...

This guideline provides updated recommendations for acute reversal of anticoagulation after ICH, highlighting use of protein complex concentrate for reversal of vitamin K antagonists such as warfarin, ...

In response to the FDA's feedback, Axsome plans to conduct an additional controlled trial that will use a fixed-dose paradigm ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

BLA accepted for Priority Review Fam-trastuzumab deruxtecan-nxki (AstraZeneca and Daiichi Sankyo) Human epidermal growth factor receptor 2 (HER2)-directed antibody + topoisomerase inhibitor conjugate ...

Like methylphenidate, lisdexamfetamine is a CNS stimulant and acts as a norepinephrine and dopamine reuptake inhibitor (NDRI). This drug is known under the brand name, among others, as Elvanse and ...

Enna Cocaine is a monoamine transport inhibitor. Current models attributing pharmacologic ... Cocaine inhibition of the dopamine, serotonin, and norepinephrine transporters is relatively weak, ...

It is a first-in-class combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor (NRI). Their combined pharmacological synergy targets the ...